Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies
Journal of Clinical Microbiology · 11.11.2026 · 64 (11)
DOI: 10.1128/jcm.00931-26 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 11.11.2026. Verfasst von Marie Roccon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Virologie, Université Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France. Hauptthemen laut MEDLINE: Herpesvirus 2, Human, Immunoglobulin G, Antibodies, Viral, Herpesvirus 1, Human. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: bioMérieux.
Abstract (Originalsprache)
Type-specific serologic detection of IgG antibodies to herpes simplex virus (HSV)-1 and HSV-2 provides important diagnostic and epidemiological information. Novel assays are under development and require rigorous evaluation before routine clinical implementation. We compared the VIDAS HSV 1&2 IgG prototype assay (bioMérieux) with the widely used LIAISON HSV-1 and HSV-2 IgG assays (DiaSorin). Western blot (WB) analysis was used as the reference method to resolve discrepant results. A total of 501 serum samples from 348 patients were analyzed, including 259 patients with PCR-confirmed HSV-1 or HSV-2 infection. WB was performed on the 89 discordant samples between the two assays. For HSV-1 IgG detection, the VIDAS prototype assay showed a sensitivity of 95.4% and a specificity of 98.6%, compared with 98.9% and 94.9%, respectively, for the LIAISON HSV-1 IgG assay. For HSV-2 IgG, the VIDAS assay demonstrated a sensitivity of 100% but a lower specificity of 90.7%, whereas the LIAISON HSV-2 IgG assay showed a lower sensitivity of 88.2% and a higher specificity of 99.4%. Approximately 30% of the samples with high HSV-1 IgG index values yielded false-positive HSV-2 IgG results with the VIDAS assay. The receiver operating characteristic curve analysis indicated that increasing the VIDAS HSV-2 positivity threshold from 0.063 to 0.137 improved specificity to 98.9% while maintaining a sensitivity of 95.4%. For HSV-1 IgG detection, the VIDAS prototype assay showed performance comparable to that of the LIAISON assay. For HSV-2 IgG, optimization of the positivity threshold may substantially improve specificity, an important consideration in low-prevalence populations. IMPORTANCE Type-specific serology is an important complement to molecular diagnosis of herpes simplex virus (HSV) infections, helping distinguish primary, recurrent, and non-primary infections; assess neonatal transmission risk; and support patient counseling. Because western blot, the reference method, is not routinely available, the clinical value of HSV serology relies on the performance of automated immunoassays. We evaluated a novel VIDAS HSV 1&2 IgG biplex prototype assay and compared it with a widely used commercial assay. The VIDAS assay showed performance comparable to the LIAISON assay for HSV-1 IgG detection while offering simultaneous detection of HSV-1 and HSV-2 antibodies in a single test. For HSV-2 IgG, however, false-positive results were observed, particularly in samples with high HSV-1 antibody levels. Importantly, optimizing the HSV-2 positivity threshold improved specificity while maintaining high sensitivity. These findings provide data for assay optimization before commercialization and highlight the need to balance sensitivity and specificity for accurate clinical interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire de Virologie, Université Grenoble Alpes, CHU Grenoble Alpes, Grenoble, France.
- Laboratoire de Virologie, Université Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), CHU Grenoble Alpes, Grenoble, France.
- Service d'Infectiologie, Université Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), CHU Grenoble Alpes, Grenoble, France.
ORCID-Profile: Aurélie Truffot, Olivier Epaulard, Raphaële Germi, Julien Lupo
Förderung
- bioMérieux
Zitieren
APA
Roccon, M., Charly, H., Truffot, A., Pelletier, L., Morand, P., Epaulard, O., Germi, R., & Lupo, J. (2026). Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies. Journal of Clinical Microbiology, 64(11). https://doi.org/10.1128/jcm.00931-26
Vancouver
Roccon M, Charly H, Truffot A, Pelletier L, Morand P, Epaulard O, et al. Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies. Journal of Clinical Microbiology. 2026;64(11). doi:10.1128/jcm.00931-26
BibTeX
@article{Roccon2026,
author = {Roccon, Marie and Charly, Hardy and Truffot, Aurélie and Pelletier, Laurent and Morand, Patrice and Epaulard, Olivier and Germi, Raphaële and Lupo, Julien},
title = {Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {11},
doi = {10.1128/jcm.00931-26}
}
EUVIMED